Weekly epirubicin in patients with hormone-resistant prostate cancer

The aim of this study was to investigate the benefit of weekly epirubicin in the treatment of metastatic hormone-resistant prostate cancer. One hundred and forty-eight patients with metastatic hormone-resistant prostate cancer received weekly 30-min intravenous infusions of epirubicin 30 mg m(2) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrioli, R, Fiaschi, A I, Pozzessere, D, Messinese, S, Sabatino, M, Marsili, S, Correale, P, Manganelli, A, Salvestrini, F, Francini, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364259/
https://www.ncbi.nlm.nih.gov/pubmed/12232753
http://dx.doi.org/10.1038/sj.bjc.6600525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364259/
https://www.ncbi.nlm.nih.gov/pubmed/12232753
http://dx.doi.org/10.1038/sj.bjc.6600525

Ejemplares similares